Stockscreener 앱 받기
3.55
5.65%
0.19
전일 마감가:
$3.36
열려 있는:
$3.33
하루 거래량:
407.92K
Relative Volume:
0.70
시가총액:
$151.55M
수익:
-
순이익/손실:
$-32.74M
주가수익비율:
-4.3293
EPS:
-0.82
순현금흐름:
$-24.89M
1주 성능:
+0.57%
1개월 성능:
+2.90%
6개월 성능:
-71.85%
1년 성능:
-59.38%
1일 변동 폭
$3.33
$3.55
1주일 범위
$3.33
$3.68
52주 변동 폭
$3.18
$16.94
Third Harmonic Bio Inc Stock (THRD) Company Profile
명칭
Third Harmonic Bio Inc
전화
(209) 727-2457
주소
1700 MONTGOMERY STREET, SAN FRANCISCO
THRD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
3.55 | 151.55M | 0 | -32.74M | -24.89M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-11 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-07 | 개시 | Raymond James | Outperform |
| 2022-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-15 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-10 | 개시 | Cowen | Outperform |
| 2022-10-10 | 개시 | Jefferies | Buy |
| 2022-10-10 | 개시 | Morgan Stanley | Overweight |
모두보기
Third Harmonic Bio Inc 주식(THRD)의 최신 뉴스
Third Harmonic Bio initiates process to identify opportunities to maximize value - TipRanks
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Hold Rating for Third Harmonic Bio, Inc. Amid Strategic Exploration and Cautious Development Approach - TipRanks
Stifel Downgrades Third Harmonic Bio (THRD) - MSN
Stifel Nicolaus Downgrades Third Harmonic Bio to Neutral From Buy, Adjusts Price Target to $5 From $23 - MarketScreener
Third Harmonic Bio Reports 2024 Financial Results and Strategic Plans - TipRanks
Third Harmonic Bio reports FY24 EPS ($1.09) vs. (78c) last year - TipRanks
Stifel cuts Third Harmonic stock rating to hold, slashes target to $5 - Investing.com
Third Harmonic Bio Q4 Net Income USD -13.1 Million - Marketscreener.com
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Third Harmonic Bio, Inc. Announces Rise In Full Year Profit - Nasdaq
Third Harmonic's $285M War Chest Powers Phase 2 CSU Drug Development Amid Strategic Shift - Stock Titan
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; ElevateBio trims team - Fierce Biotech
Third Harmonic Bio Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
2025 R&D layoffs tracker: 53,686 and counting - R&D World
Third Harmonic Bio Advances THB335 for Inflammatory Diseases - TipRanks
THB-335 counteracts cutaneous anaphylaxis in vivo - BioWorld Online
Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - Citeline
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth - Yahoo Finance
Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James - MSN
Third Harmonic Bio progresses THB335 to Phase 2 trial - MSN
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD) - Nasdaq
Third Harmonic stock rating cut by Raymond James - MSN
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study - Yahoo Finance
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - AOL
Third Harmonic Bio Inc (THRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):